Menarini`s Tenkasi (Oritavancin) Receives Approval in Europe
MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced two important milestones for KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that was launched in July.
Melinta Therapeutics (Melinta), a commercial-stage company providing innovative therapies for acute and life-threatening illnesses, today announced the commercial launch of KIMYRSA™ (oritavancin), a lipoglycopeptide antibiotic that delivers a complete course of therapy for acute bacterial skin and skin structure infections (ABSSSI) in a single, one hour, 1,200 mg infusion. The U.S. Food and Drug Administration approved KIMYRSA on March 12, 2021, for the treatment of adult patients with ABSSSI caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA).
MORRISTOWN, N.J.--(BUSINESS WIRE)--Melinta Therapeutics, LLC (Melinta), a commercial-stage company focused on the development and commercialization of novel antibiotics, today announced that the U.S. Food and Drug Administration (FDA) has approved KIMYRSA™ (oritavancin) for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of designated Gram-positive microorganisms, including methicillin-resistant Staphylococcus aureus (MRSA). KIMYRSA is a lipoglycopeptide antibiotic that delivers a complete course of therapy for ABSSSI in a single, one hour 1,200 mg infusion.
Antibiotic biotechs often struggle to turn their products into commercial triumphs, and that's certainly been the case for New Haven, Connecticut-based Melinta Therapeutics, which ultimately filed for bankruptcy in late 2019. But Melinta hopes its newly minted drug can become an exception, thanks to a convenience edge over rivals.
FLORENCE , Italy, October 11, 2018 / PRNewswire /Trade agreement expands the x istente and joint development for delafloxacin Consolidates the company's strategic objective on infectious diseases Menarini Group, an Italian biopharmaceutical company present in 136 countries around the world, and Melinta Therapeutics, a company based in the United States dedicated to the discovery, development and commercialization of new antibiotics to treat serious bacterial infections, announced an agreement according to which Menarini will acquire the exclusive rights to market meropenem / vaborbactam (Vabomere [TM] in the United States), oritavancin (Orbactiv ® ) and minocycline IV (Minocin IV ® ) in 68 countries in Europe, in Asia-Pacific including China , South Korea and Australia (excluding Japan), and in the Commonwealth of Independent States (CIS), including Russia.
FLORENCE , Italy, October 11, 2018 / PRNewswire /Trade agreement expands the x istente and joint development for delafloxacin Consolidates the company's strategic objective on infectious diseases Menarini Group, an Italian biopharmaceutical company present in 136 countries around the world, and Melinta Therapeutics, a company based in the United States dedicated to the discovery, development and commercialization of new antibiotics to treat serious bacterial infections, announced an agreement according to which Menarini will acquire the exclusive rights to market meropenem / vaborbactam (Vabomere [TM] in the United States), oritavancin (Orbactiv ® ) and minocycline IV (Minocin IV ® ) in 68 countries in Europe, in Asia-Pacific including China , South Korea and Australia (excluding Japan), and in the Commonwealth of Independent States (CIS), including Russia.
NEW HAVEN, Conn., May 29, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced that the underwriters of its recently announced public offering of 22,000,000 shares of its common stock have exercised in full their option purchase an additional 2,640,000 shares.
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, today announced a significant corporate presence at the upcoming Making a Difference in Infectious Diseases (MAD-ID) 2018 Annual Meeting from May 9-12, 2018 in Orlando, Florida. Melinta will be presenting 12 posters summarizing results from clinical and in vitro studies of Baxdela™ (delafloxacin), Orbactiv® (oritavancin) for injection and Vabomere™ (meropenem and vaborbactam).
Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial infections, today announced the successful completion of its previously announced acquisition of The Medicines Company’s (NASDAQ:MDCO) infectious disease business.